Following bluebird bio Inc’s (NASDAQ:BLUE) first research and development (R&D) meeting, Cowen top analyst Eric Schmidt shares insight on the firm’s preclinical strides …
At the European Society for Medical Oncology (ESMO) conference, Incyte Corporation (NASDAQ:INCY) presented updated data from its Phase I trial of epacadostat and …
Cowen top analyst Eric Schmidt is out with his commentary on shares of Celgene Corporation (NASDAQ:CELG) after the biotech giant released preliminary data …
Celegene raised prices for pipeline drugs Revlimid and Pomalyst by 3%
Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted second-quarter financial results and provided a clinical progress update. Despite many of the drug maker’s pipeline candidates continuing to make …
Ever since Exelixis, Inc. (NASDAQ:EXEL) gained approval from the FDA allowing its pipeline drug to be released for treatment of second-line advanced renal …
At a recent dinner with brokerage firm Cowen, CFO Peter Kellogg and Inflammation & Immunology (I&I) President Scott Smith of Celgene Corporation (NASDAQ:CELG) …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares are down over 8% this morning, after the cancer drug maker reported second-quarter results, with net Onivyde sales of …
Yesterday morning, California-based biopharm company Ionis Pharmaceuticals Inc (NASDAQ:IONS) made a positive stride with its clinical drug nusinersen, announcing that major motor milestones were achieved …
Cowen analyst Eric Schmidt weighed in today with a few insights on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), after the company reported second-quarter financials and provided investors …